In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $67.21, marking a +1.04% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $72.31, demonstrating a -2.24% change from the preceding day's closing price. Elsewhere, the Dow saw an upswing of 0.47%, while the ...

CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.